Suchergebnisse
Suchergebnisse:
Vor einem Tag · Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area.
Vor einem Tag · Colorectal cancer ( CRC ), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine ). [5] Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, abdominal pain and fatigue. [9] Most colorectal cancers are due to old age ...
Vor einem Tag · Published: 09:15 29 May 2024 EDT. Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed ‘a 180’ turn since the peak of Covid vaccines interest in the ...
Vor einem Tag · BTC, including gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma, account for <1% of all adult cancers globally and are often associated with a poor prognosis 1,2. The human epidermal growth factor receptor 2 (HER2) is a well-validated target for antitumor therapy in other cancers. Across the U.S., Europe , and Japan , approximately 12,000 people are diagnosed with HER2 ...
Vor 22 Stunden · You can still register for the next ILCA #webinar! In less than two hours our speakers will share their perspectives on the latest advancements in liver…
Vor einem Tag · About Biliary Tract Cancer BTC, including gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma, account for < 1% of all adult cancers globally and are often associated with a poor prognosis 1,2. The human epidermal growth factor receptor 2 (HER2) is a well-validated target for antitumor therapy in other cancers.
Vor einem Tag · Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date of November 29, 2024. "The priority review designation for zanidatamab underscores the critical need for new ...
